WARNING: LATUDA® (lurasidone) ASSOCIATED WITH STROKE, KIDNEY FAILURE, LIVER FAILURE
Latuda® (lurasidone) and Stroke
As of August 28th 2013, MedlinePlus (an online encyclopedia curated by the National Institutes of Health and the US National Library of Medicine) has included a new, and very serious warning on its Latuda® (lurasidone) page. Latuda® (lurasidone) is an antipsychotic medication manufactured by Sunovion Pharmaceuticals, Inc., and is used primarily in the treatment of schizophrenia.
This warning states that adults with dementia “have an increased chance of death during treatment [with Lurasidone]. Older adults with dementia may also have a greater chance of having a stroke or ministroke during treatment with antipsychotics.” (emphasis added)
MedlinePlus also warns that “Lurasidone is not approved by the Food and Drug Administration (FDA) for the treatment of behavior disorders in older adults with dementia.” [Click here for the full MedlinePlus on Latuda]
Latuda® (lurasidone) Kidney Failure; Latuda® (lurasidone) Liver Failure
For at least two years, the medical community has known that Latuda® (lurasidone) is associated with an increased risk for kidney damage and kidney failure (renal damage, renal failure), and that Latuda® (lurasidone) is associated with increased risk for liver damage and liver failure (hepatic damage, hepatic failure).
In August 2011, the medical journal The Consultant Pharmacist (“the official peer-reviewed journal of the American Society of Consultant Pharmacists”) published a paper titled “Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population.” that demonstrated the efficacy of Latuda (lurasidone) but also states “renal and hepatic impairment substantially affect the drug’s pharmacokinetics, necessitating dose reduction or limitation.”
Additionally, in November 2012, a Journal of Psychiatric Practice article was published addressing Lurasidone and kidney failure. By the tone of the comment in the Consultant Pharmacist journal and the publication in Journal of Psychiatric Practice, one can tell the scientific community has agreed that Latuda definitely carries risk for both kidney and liver failure.
Another article, published in the July-August 2012 edition of The annals of pharmacotherapy titled “Lurasidone: an atypical antipsychotic for schizophrenia.” states that Latuda “is pregnancy category B, is contraindicated for coadministration with strong CYP3A4 inducers and inhibitors, and requires dose adjustments with certain medications and in renal and hepatic impairment. [... And,] it is a potent 5-HT(7) antagonist, which may impact depression and cognition.”
Latuda Fact Sheet and Warning Labels
Here is a link to the Latuda Fact Sheet provided by Sunovion, that notes the risk for liver and kidney damage and warns against use in dementia.
This is the Latuda Black Box Warning, that advises against use in dementia but makes no mention of kidney or liver problems.
Since many people have used Latuda® (lurasidone) unaware of the possibility of kidney failure, liver failure, and increased risk of death during treatment, a number of Latuda® lawsuits are currently being filed. If you or a loved one used Latuda® (lurasidone) and suffered an unannounced Latuda® side-effect, you may be entitled to significant financial compensation for the injuries you have have suffered by no fault of your own.
For more information on Latuda®, or for a free, no-obligation case consultation, contact our team of Latuda® lawyers at the information provided below. We have the experience, resources, and skills required to win the justice you deserve, even from the largest of pharmaceutical manufacturers. There is no reason for you to fight this alone. Call today and see how we can help!
(855) 452 – 5529